

Charcoal Agar Base, HiVeg™

MV344

Intended Use:

With supplements it is recommended for the cultivation of *Bordetella pertussis* for vaccine production and also for the maintenance of stock cultures.

Composition**

Ingredients	g / L
HiVeg™ infusion	12.000
HiVeg™ peptone	10.000
Yeast extract	3.500
Starch, soluble	10.000
Charcoal	4.000
Sodium chloride	5.000
Agar	18.000
Final pH (at 25°C)	7.3±0.2

**Formula adjusted, standardized to suit performance parameters

Directions

Suspend 31.25 grams in 450 ml purified / distilled water. Heat to boiling to dissolve the medium with frequent stirring. Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes. Cool to 45-50°C. Aseptically add sterile 10% of defibrinated blood and rehydrated contents of 1 vial of Bos Selective Supplement (FD004). Mix well and pour into sterile Petri plates. Charcoal Agar can be converted to Chocolate Agar for isolation of *Haemophilus* species.

Principle And Interpretation

The genus *Bordetella* contains four species: *Bordetella pertussis*, *Bordetella parapertussis*, *Bordetella bronchiseptica* and *Bordetella avium* (1). Genetic studies have shown that these organisms are very closely related to each other. Humans are the only host of *B.pertussis* and *B.parapertussis*, while *B.bronchiseptica* is found in a wide variety of animals and occasionally found in humans (2). *B.avium* is found in birds. *Bordetella* species are obligately aerobic and metabolically not very active. They are non-motile except *B. bronchiseptica*. *B.pertussis* is the major cause of whooping cough or pertussis.

B.parapertussis is associated with a milder form of the disease (3). Primary isolation of *B.pertussis* in particular, requires the addition of charcoal, 15-20% blood to neutralize the growth-inhibiting effects. Isolation of this organism requires enrichment medium.

Charcoal Agar is prepared according to the method of Mishulow, Sharpe and Cohen (2). This medium can be used as a replacement for Bordet-Gengou Agar for isolation of *B. pertussis* and for the production of *B.pertussis* vaccines. Charcoal Agar supplemented with horse blood can also be used for the cultivation and isolation of *Haemophilus influenzae* (4).

The difficulty in the isolation of *Bordetella pertussis* from nasopharyngeal secretions is the repression of unwanted flora during the long incubation period on nutritious media. Penicillin can be added to the medium as an antimicrobial agent for restricting the other contaminants. However Penicillin resistant floras still cause contamination, which as observed by Lacey (5). Methicillin was found to be superior than Penicillin in suppressing unwanted nasopharyngeal flora as observed by Broome et al (6). Sutcliffe and Abbott found that Cephalexin was still better than Methicillin (7). Charcoal Agar Base, HiVeg™ is prepared by completely replacing animal based peptone with vegetable peptones to avoid BSE/TSE risks associate with animal peptones.

The ingredients like HiVeg™ infusion, HiVeg™ peptone,, yeast extract provide essential nutrients to the organisms. Sodium chloride maintains osmotic balance. Starch soluble and charcoal neutralizes substances toxic to *Bordetella* species such as fatty acids. Charcoal has the tendency to settle at the bottom of the flask. Therefore, before dispensing, swirl the flasks gently to obtain a uniform charcoal suspension (8).

Examine plates after 40 hours incubation and twice daily thereafter. Small shiny grayish white, round corner, colonies of *Bordetella* species are observed on plates. Confirm the findings with DFA i.e. Direct Fluorescent Antibody testing. To make earlier diagnosis, perform direct fluorescent antibody testing on the secretion.

Type of specimen

Nasal swabs

Specimen Collection and Handling

Collect the nasal swabs in early stage of the illness and place in tubes of half strength Charcoal Agar Base supplemented with 10% v/v lysed defibrinated horse blood and Bos Selective Supplement (FD004). Generously inoculate the swabs on to thick layer of Charcoal Agar Base containing 10% v/v blood and Bos Selective Supplement (FD004). Non-selective medium (without FD004) may be used in addition. Replace the swab in the original transport medium and hold at room temperature. Incubate the plates at 35°C in a moist atmosphere (60-70% humidity) upto 6 days. After use, contaminated materials must be sterilized by autoclaving before discarding.

Warning and Precautions

Read the label before opening the container. Wear protective gloves/protective clothing/eye protection/ face protection. Follow good microbiological lab practices while handling specimens and culture. Standard precautions as per established guidelines should be followed while handling clinical specimens. Safety guidelines may be referred in individual safety data sheets.

Limitations

1. Swirl the flask gently when dispensing to obtain a uniform charcoal suspension.
2. Confirm the findings with DFA i.e. Direct Fluorescent Antibody testing.

Performance and Evaluation

Performance of the medium is expected when used as per the direction on the label within the expiry period when stored at recommended temperature.

Quality Control

Appearance

Grey to greyish black homogeneous free flowing powder

Gelling

Firm, comparable with 1.8% Agar gel

Colour and Clarity of prepared medium

Black coloured, opaque gel with undissolved black particles forms in Petri plates

Reaction

Reaction of 6.25% w/v aqueous solution at 25°C. pH : 7.3±0.2

pH

7.10-7.50

Cultural Response

Cultural characteristics observed with added sterile defibrinated blood and Bos Selective Supplement (FD004), after an incubation at 35 - 37°C for 24 - 48 hours

Organism	Inoculum (CFU)	Growth	Recovery
<i>Bordetella bronchiseptica</i> ATCC 4617	50-100	good-luxuriant	≥50%
<i>Bordetella parapertussis</i> ATCC 15311	50-100	good-luxuriant	≥50%
<i>Bordetella pertussis</i> ATCC 8467	50-100	good-luxuriant	≥50%
<i>Staphylococcus aureus</i> subsp. <i>aureus</i> ATCC 25923 (00034*)	≥10 ⁴	inhibited	0%
<i>Klebsiella pneumoniae</i> ATCC 13883 (00097*)	≥10 ⁴	inhibited	0%

Key : (*) Corresponding WDCM numbers

Storage and Shelf Life

Store between 10-30°C in a tightly closed container and the prepared medium at 2-8°C. Use before expiry date on the label. On opening, product should be properly stored dry, after tightly capping the bottle in order to prevent lump formation due to the hygroscopic nature of the product. Improper storage of the product may lead to lump formation. Store in dry ventilated area protected from extremes of temperature and sources of ignition. Seal the container tightly after use. Product performance is best if used within stated expiry period.

Disposal

User must ensure safe disposal by autoclaving and/or incineration of used or unusable preparations of this product. Follow established laboratory procedures in disposing of infectious materials and material that comes into contact with sample must be decontaminated and disposed of in accordance with current laboratory techniques (9,10).

Reference

1. Murray P. R., Baron J. H., Pfaller M. A., Jorgensen J. H. and Tenover F. C., (Ed.), 2003, Manual of Clinical Microbiology, 8th Ed., American Society for Microbiology, Washington, D.C.
2. Mishulow, Sharpe and Cohen, 1953, Am. J. Public Health, 43:1466.
3. Ensminger P. W., Gulberston C. G. and Powell H. M., 1953. J. Infect. Dis., 93(3):266.
4. Lacey B. W., 1954, J. Hyg., 59:273
5. Broome C. V., Fraser D. W. and English J. W., 1979, Internat. Symp. on Pertussis DHEW J., Washington D.C., pp 19-29.
6. Sutcliffe E. M. and Abbott J. D., 1979, B.M.J. II: 732-733.
7. MacFaddin J. F., 1985, Media for Isolation-Cultivation-Identification-Maintenance of Medical Bacteria, Vol. I, Williams and Wilkins, Baltimore.
8. Young S. A., Anderson G. L. and Mitchell P. D., 1987, Clin. Microbiol. Newsletter, 9, 176-179.
9. Isenberg, H.D. Clinical Microbiology Procedures Handbook 2nd Edition.
10. Jorgensen, J.H., Pfaller, M.A., Carroll, K.C., Funke, G., Landry, M.L., Richter, S.S and Warnock., D.W. (2015) Manual of Clinical Microbiology, 11th Edition. Vol. 1.

Revision : 07 / 2024

Disclaimer :

User must ensure suitability of the product(s) in their application prior to use. Products conform solely to the information contained in this and other related HiMedia™ publications. The information contained in this publication is based on our research and development work and is to the best of our knowledge true and accurate. HiMedia™ Laboratories Pvt Ltd reserves the right to make changes to specifications and information related to the products at any time. Products are not intended for human or animal or therapeutic use but for laboratory, diagnostic, research or further manufacturing use only, unless otherwise specified. Statements contained herein should not be considered as a warranty of any kind, expressed or implied, and no liability is accepted for infringement of any patents.